PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Emergent BioSolutions, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Emergent BioSolutions Co-Hosts Biopreparedness Conference with the French High Committee for Civil Defense - Emergent BioSolutions, Inc. (NYSE: EBS) is co-hosting
Emergent BioSolutions Co-Hosts Biopreparedness Conference with the French High Committee for Civil Defense

 

NewswireToday - /newswire/ - Rockville, MD, United States, 2011/09/09 - Emergent BioSolutions, Inc. (NYSE: EBS) is co-hosting "Anthrax: Threat and Response," a conference organized by the French High Committee for Civil Defense to discuss anthrax preparedness and response - EBSI.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The conference, which brings together military and civilian representatives involved in biological threat management in France, features topics on research programs, threat detection, hospital and medical chain preparedness, anthrax prevention through vaccination, decontamination of critical infrastructure, and global response strategies.

"This is a very important conference, where France's experts discuss the issues and challenges of a terrorist anthrax attack," said Dr. Nigel Lightfoot CBE, former Director of the Health Protection Agency, U.K. and Chair Advisor, Global Health Security Initiative, U.K. Department of Health. "They have shared their preparedness measures thus far and the research that supports their capability development. Other groups who are working towards anthrax preparedness could benefit from some of this research. It was also mentioned that France has made progress in its vaccine development utilizing protective antigen and killed spores, but it is years away from licensure. They recognize, and I strongly believe, that stockpiling of anthrax vaccines, as practiced by the U.S. and the U.K., is an essential component of the response."

"Emergent is pleased to co-host this conference as part of our efforts to raise global awareness of biopreparedness," said Allen Shofe, Senior Vice President Corporate Affairs, Emergent BioSolutions. "In this dialogue and sharing of best practices, we hope to leverage our company's extensive experience in the development, manufacture, and delivery of medical countermeasures that are a critical component of the U.S. government's biodefense strategy for national security."

"We have organized this conference on the anthrax threat and response that gathers experts in the field from France, the United States, and United Kingdom, to discuss the anthrax threat status and the response cycle ranging from detection to medical countermeasures and decontamination," said Christian Sommade, Managing Director of the French High Committee for Civil Defense. "We thank our public and private sponsors for their support."

Attendees include researchers, physicians, first responders, and high level officials in charge of procurement and deployment of detection, medical countermeasures, and decontamination initiatives. Representatives of the European Commission and the U.K. government have equally been involved in this unique exchange of experiences and best practices from France, the U.S. and the U.K.

The French High Committee for Civil Defense is an international non-profit organization composed of State Assemblies, community leaders, and other stakeholders focused on issues related to national security. It works to provide better protection of the French population and businesses, and enhanced resilience of the nation against major risks and threats. The conference is being held today in Paris, France.

About Emergent BioSolutions, Inc.
Emergent BioSolutions (emergentbiosolutions.com) protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology, and autoimmune disorders.

Investors Contact:
Emergent BioSolutions
Robert G. Burrows, Vice President, Investor Relations
P: +1 301-795-1877 / E: BurrowsR[.]ebsi.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Emergent BioSolutions, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Emergent BioSolutions Co-Hosts Biopreparedness Conference with the French High Committee for Civil Defense

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tracey Schmitt - EBSI.com 
301-795-1800 SchmittT[.]ebsi.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Emergent BioSolutions, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Emergent BioSolutions, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)